Company Overview
Company Type: Private Company
Website: www.plantformcorp.com
Number of Employees: -
Year Founded: 2008
Total Amount Raised (CAD mm)†: 22.66
Total Rounds of Funding**:2
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
PlantForm Corporation, a biotech company, manufactures and sells plant-made pharmaceuticals, including monoclonal antibodies, therapeutic proteins, and vaccines for the treatment of cancer, HIV/AIDS, Ebola virus, and other life-threatening illnesses. The company develops vivoXPRESS, a molecular farming platform that uses tobacco plants (nicotiana benthamiana and tobaccum) to produce various biologic (large molecule) drugs, including monoclonal antibodies and therapeutic proteins. Its pipeline includes various biosimilar drugs for breast cancer; antibodies for HIV/AIDS and Ebola virus (Sudan strain); and Butyrylcholinesterase, an enzyme that provides prophylactic protection against nerve agents, such as sarin gas. The company serves customers worldwide. PlantForm Corporation was founded in 2008 and is based in Guelph, Canada. It has additional offices in Sarnia and Toronto, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Hosking, Ronald G.
Founder, CFO & Chairman of the Board
Stewart, Donald 
Chief Executive officer, President and Director
Cayea, David
Chief Operating Officer
Cossar, Doug
Vice President of Research and Chair of the Scientific Advisory Board

Key Board Members
Name
Title
Hosking, Ronald G.
Founder, CFO & Chairman of the Board
Stewart, Donald 
Chief Executive officer, President and Director
Cossar, Doug
Vice President of Research and Chair of the Scientific Advisory Board
Berger, Stuart A.
Member of the Scientific Advisory Board
Clark, Bruce D.
Director
Devine, Malcolm 
Member of Scientific Advisory Board
Fraser, David A.
Director
Goldberg, Mark 
Director
Hughes, Kenneth
Member of Scientific Advisory Board
Modi, Pankaj 
Member of the Scientific Advisory Board
Narod, Steve 
Member of Scientific Advisory Board
Rothstein, Steven 
Member of Scientific Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
120 Research Lane Suite 200 | Guelph, ON | N1G 0B4 | Canada
Phone: 416 572 7795   Fax: 416 572 7501

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
MaRs Discovery District, Investment Arm
-
Unknown
-
-
Ontario Centres of Excellence, Inc., Investment Arm
-
Unknown
-
-
Ruffena Capital Ltd
-
Unknown
-
-
York Medtech Partners Inc.
-
Minority
-
-


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-19-2013
Aug-19-2013
Private Placement
Target
PlantForm Corporation


1.94
Sep-15-2011
-
Private Placement
Target
PlantForm Corporation


20.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-26-2021
Client Announcements
PlantForm Corporation and POSCO International Sign Agreement to Market Classical Swine Fever Vaccine Globally
Apr-06-2021
Client Announcements
PlantForm Corporation Signs Agreement with Bio-Manguinhos/Fiocruz to Develop A Biosimilar Pembrolizumab Cancer Drug
Nov-16-2020
Client Announcements
Cape Biologix Technologies, Inno-3B and PlantForm Corporation Announces Agreements to Commercialize COVID-19 antibody blood test
Apr-07-2020
Strategic Alliances
Plantform Corporation Joins Forces with Cape Bio Pharms, Inno-3B and Microbix Biosystems Inc. to Develop Serology Tests to Detect Antibodies Specific to COVID-19
Oct-03-2017
Company Conference Presentations
PlantForm Corporation Presents at Defense Innovation Summit, Oct-03-2017 03:20 PM


Advisors
Private Placement Advisors
Gowling WLG International Limited, Landmark Capital S.A.


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 18, 2023 03:44 AM
PlantForm Corporation
PlantForm Corp
Reports
43
GlobalData

Sep 14, 2023 11:31 PM
PlantForm Corporation
PlantForm Corp - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
18
GlobalData

Dec 14, 2022 02:36 AM
PlantForm Corporation
PlantForm Corp
Reports
44
GlobalData

Dec 10, 2022 02:44 AM
PlantForm Corporation
PlantForm Corp - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
18
GlobalData

Sep 20, 2022 07:21 AM
PlantForm Corporation
PlantForm Corp
Reports
44
GlobalData

Sep 15, 2022 03:52 AM
PlantForm Corporation
PlantForm Corp - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
18
GlobalData

Jun 18, 2022 03:29 AM
PlantForm Corporation
PlantForm Corp
Reports
44
GlobalData

Jun 10, 2022 09:22 AM
PlantForm Corporation
PlantForm Corp - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
18
GlobalData

Mar 15, 2022 04:54 AM
PlantForm Corporation
PlantForm Corp
Reports
44
GlobalData

Mar 11, 2022 05:47 AM
PlantForm Corporation
PlantForm Corp - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
18


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Hosking, Ronald G.
Founder, CFO & Chairman of the Board
416 572 7795
416 572 7501
ron.hosking@plantformcorp.com
Stewart, Donald 
Chief Executive officer, President and Director
416 572 7795
416 572 7501
-
Cossar, Doug
Vice President of Research and Chair of the Scientific Advisory Board
416 572 7795
416 572 7501
-
Berger, Stuart A.
Member of the Scientific Advisory Board
416 572 7795
416 572 7501

Clark, Bruce D.
Director
416 572 7795
416 572 7501

Devine, Malcolm 
Member of Scientific Advisory Board
416 572 7795
416 572 7501

Fraser, David A.
Director
416 572 7795
416 572 7501

Goldberg, Mark 
Director
416 572 7795
416 572 7501
mark.goldberg@plantformcorp.com
Hughes, Kenneth
Member of Scientific Advisory Board
416 572 7795
416 572 7501
-
Modi, Pankaj 
Member of the Scientific Advisory Board
416 572 7795
416 572 7501

Narod, Steve 
Member of Scientific Advisory Board
416 572 7795
416 572 7501

Rothstein, Steven 
Member of Scientific Advisory Board
416 572 7795
416 572 7501

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Hosking, Ronald G.
Founder, CFO & Chairman of the Board
416 572 7795
416 572 7501
ron.hosking@plantformcorp.com
Stewart, Donald 
Chief Executive officer, President and Director
416 572 7795
416 572 7501
-
Cayea, David
Chief Operating Officer
416 572 7795
416 572 7501
david.cayea@plantformcorp.com
Cossar, Doug
Vice President of Research and Chair of the Scientific Advisory Board
416 572 7795
416 572 7501
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
